Mezigdomide
Phase 3Small molecule
Bristol-Myers SquibbMezigdomide is one of 117 small molecule programs targeting Extramedullary Disease in Multiple Myeloma. It is currently in Phase 3.
5
Indications
19
Total Trials
15
Active Trials
116
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Empliciti
Bristol-Myers SquibbPhase 3
Fludara
SanofiPhase 3
TALVEY
Johnson & JohnsonPhase 3
Ninlaro
TakedaPhase 3
Biaxin
AbbViePhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Neulasta
AmgenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma11 trials
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Recruiting·—·Phase 1·NCT06048250·15 enrolled
Show 8 more trials
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT06121843·187 enrolled
Hepatic Impairment1 trial
Relapsed or Refractory1 trial
4 more indications
Relapsed or Refractory Multiple Myeloma1 trial
Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mezigdomide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company